Sandy Srinivas

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis
    Kelly Morgan
    Department of Urology, Stanford University School of Medicine and Palo Alto Veterans Affairs Medical Center, Stanford, California, USA
    Urology 64:808-9. 2004
  2. ncbi request reprint Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer
    David Feldman
    Department of Medicine Endocrinology, Stanford University School of Medicine, 300 Pasteur Drive, Room S 025, Stanford, CA 94305 5103, USA
    Nutr Rev 65:S113-5. 2007
  3. pmc A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, Stanford, California 94305 1205, USA
    Chemotherapy 55:321-6. 2009
  4. ncbi request reprint Bone related events in high risk prostate cancer
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    J Urol 176:S50-4. 2006
  5. ncbi request reprint Nonplatinum therapy in advanced bladder cancer
    Sandy Srinivas
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Rev Anticancer Ther 6:887-94. 2006
  6. ncbi request reprint Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Urology 67:1001-6. 2006
  7. ncbi request reprint A phase II trial of calcitriol and naproxen in recurrent prostate cancer
    Sandy Srinivas
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Anticancer Res 29:3605-10. 2009
  8. ncbi request reprint A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma
    Sandy Srinivas
    Division of Oncology, Stanford Medical Center, Stanford, CA, USA
    BJU Int 96:536-9. 2005
  9. ncbi request reprint A nonplatinum combination in metastatic transitional cell carcinoma
    Sandy Srinivas
    Stanford University Medical Center, Stanford, California, USA
    Am J Clin Oncol 28:114-8. 2005
  10. doi request reprint The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer
    Lauren C Harshman
    Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Am J Clin Oncol 31:417-23. 2008

Detail Information

Publications30

  1. ncbi request reprint Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis
    Kelly Morgan
    Department of Urology, Stanford University School of Medicine and Palo Alto Veterans Affairs Medical Center, Stanford, California, USA
    Urology 64:808-9. 2004
    ..An incidentally discovered testicular mass in a man with high-grade, invasive bladder cancer should be considered a metastatic lesion until proven otherwise...
  2. ncbi request reprint Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer
    David Feldman
    Department of Medicine Endocrinology, Stanford University School of Medicine, 300 Pasteur Drive, Room S 025, Stanford, CA 94305 5103, USA
    Nutr Rev 65:S113-5. 2007
  3. pmc A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, Stanford, California 94305 1205, USA
    Chemotherapy 55:321-6. 2009
    ..We conducted a phase II study to evaluate the efficacy and safety of docetaxel and oxaliplatin in metastatic urothelial cancer patients who had received prior platinum therapy...
  4. ncbi request reprint Bone related events in high risk prostate cancer
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    J Urol 176:S50-4. 2006
    ..We provide recommendations for defining and treating bone related events in high risk prostate cancer...
  5. ncbi request reprint Nonplatinum therapy in advanced bladder cancer
    Sandy Srinivas
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Rev Anticancer Ther 6:887-94. 2006
    ..Conversely, noncisplatin-containing regimens have been shown to have a more favorable toxicity profile and to have activity in advanced bladder cancer. Here, various nonplatinum chemotherapy regimens for advanced disease are reviewed...
  6. ncbi request reprint Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer
    Sandy Srinivas
    Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Urology 67:1001-6. 2006
    ..To assess the effect of triamcinolone administration on the serum prostate-specific antigen (PSA) response and the time to progression in patients with androgen-independent prostate cancer (AIPC)...
  7. ncbi request reprint A phase II trial of calcitriol and naproxen in recurrent prostate cancer
    Sandy Srinivas
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Anticancer Res 29:3605-10. 2009
    ..The objective of the study was to determine whether treatment with calcitriol and naproxen is effective in safely delaying the growth and progression of PCa in men with early recurrent disease...
  8. ncbi request reprint A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma
    Sandy Srinivas
    Division of Oncology, Stanford Medical Center, Stanford, CA, USA
    BJU Int 96:536-9. 2005
    ....
  9. ncbi request reprint A nonplatinum combination in metastatic transitional cell carcinoma
    Sandy Srinivas
    Stanford University Medical Center, Stanford, California, USA
    Am J Clin Oncol 28:114-8. 2005
    ..The objective of this research was to determine if a combination of paclitaxel and gemcitabine would be effective in patients who were unable to receive cisplatin or have failed cisplatin treatment...
  10. doi request reprint The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer
    Lauren C Harshman
    Division of Medical Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Am J Clin Oncol 31:417-23. 2008
    ..We conducted a phase II trial to determine the efficacy and safety of the combination of thalidomide and capecitabine in mRCC...
  11. doi request reprint Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
    Lauren C Harshman
    Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Urol Oncol 31:379-85. 2013
    ..Tyrosine kinase inhibitors (TKI) have dramatically changed the management paradigm of advanced renal cell carcinoma (RCC) and are increasingly being used preoperatively to achieve cytoreduction...
  12. pmc Utilization of renal mass biopsy in patients with renal cell carcinoma
    John T Leppert
    Department of Urology, Stanford University School of Medicine, Stanford, CA Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA Electronic address
    Urology 83:774-9. 2014
    ..To examine the patient, tumor, and temporal factors associated with receipt of renal mass biopsy (RMB) in a contemporary nationally representative sample...
  13. doi request reprint A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma
    Lauren C Harshman
    Stanford Cancer Institute, Division of Oncology, Stanford School of Medicine, Stanford, CA, USA
    Clin Genitourin Cancer 11:100-6. 2013
    ....
  14. doi request reprint Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma
    Lauren C Harshman
    Stanford University School of Medicine, California 94305, USA
    Cancer Invest 27:851-6. 2009
    ..2 months with rises > 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy...
  15. ncbi request reprint Toxicities of targeted agents in advanced renal cell carcinoma
    Priti Patel
    Stanford University, Stanford, CA 94305, USA
    Curr Clin Pharmacol 6:181-8. 2011
    ..The mTor inhibitors exhibit a different toxicity profile which includes hyperglycemia and hypertriglyceridemia. Recognition and understanding the mechanism of the toxicities is crucial for optimal patient management...
  16. ncbi request reprint Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma
    Lauren C Harshman
    Fellow, Medical Oncology, Stanford University School of Medicine, Division of Medical Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Rev Anticancer Ther 7:1749-61. 2007
    ....
  17. pmc Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients
    Lauren C Harshman
    Division of Oncology and Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
    BJU Int 106:1805-11. 2010
    ..RRM1 is the primary cellular target of gemcitabine and previous studies in resected early-stage lung cancer have shown a survival benefit for patients with high expression...
  18. ncbi request reprint Positron emission tomography in the initial staging of esophageal cancer
    Sherry M Wren
    Department of Surgery, Palo Alto Veterans Hospital, 3801 Miranda Ave, Palo Alto, CA 94304, USA
    Arch Surg 137:1001-6; discussion 1006-7. 2002
    ..To assess the value of positron emission tomography (PET) compared with computed tomography (CT) in the initial staging of esophageal cancer...
  19. pmc Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study
    Lauren C Harshman
    Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
    Lancet Oncol 13:927-35. 2012
    ..We assessed the use of conditional survival--a measure that accounts for elapsed time since treatment initiation--for prognostication in patients with metastatic renal-cell carcinoma treated with first-line VEGF-targeted therapies...
  20. doi request reprint Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib
    Lauren C Harshman
    Division of Oncology, Stanford University Medical Center, CA 94305, USA
    Nat Rev Urol 6:338-43. 2009
    ..A 57-year-old woman presented to the emergency department at a community hospital with a 2-month history of fatigue and right-sided flank and abdominal pain. Noncontrast CT of the abdomen and pelvis revealed a 9.1 cm right renal mass...
  21. doi request reprint Variations in normal serum alpha-fetoprotein (AFP) levels in patients with testicular cancer on surveillance
    Priti Patel
    Division of Medical Oncology, Stanford University, CA 94305, USA
    Onkologie 35:588-91. 2012
    ..Marked variations occur after serum AFP levels normalize, creating anxiety among patients and physicians during surveillance...
  22. ncbi request reprint Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment
    Joanna Badger
    Stanford Medical Center, Stanford, CA, USA
    J Clin Oncol 23:7224-5. 2005
  23. doi request reprint The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
    Philip S Hall
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, California
    JACC Heart Fail 1:72-8. 2013
    ..The purpose of this study was to document the incidence and extent of cardiovascular toxicity among advanced renal cell carcinoma patients treated with newer targeted cancer agents...
  24. pmc The bevacizumab experience in advanced renal cell carcinoma
    Lauren C Harshman
    Division of Oncology, Stanford University School of Medicine, Stanford, California, USA
    Onco Targets Ther 3:179-89. 2010
    ..With multiple agents now available for the treatment of advanced RCC, identification of patient and tumor-specific biomarkers to inform our choice of first-line therapy and the proper sequence of subsequent therapies is imperative...
  25. ncbi request reprint Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
    Christopher R King
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305 5847, USA
    Urology 67:1229-34. 2006
    ..Prostate biopsy findings are known to undergrade prostate cancer compared with the pathologic specimens yet remain the only grade guiding disease management...
  26. ncbi request reprint Acute pancreatitis associated with sorafenib
    Mingqing Li
    Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, USA
    South Med J 100:909-11. 2007
    ..Patients should be informed of this rare but potentially serious adverse effect before initiation of sorafenib therapy. Early recognition of this complication and complete discontinuation of sorafenib are recommended...
  27. ncbi request reprint Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
    Ronald M Bukowski
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 25:4536-41. 2007
    ....
  28. doi request reprint Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
    ..The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC)...
  29. ncbi request reprint Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy
    I Jenna Liu
    Section of Urology, Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif, USA
    Urol Int 77:69-75. 2006
    ..This study was designed to determine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the evaluation of metastatic transitional cell carcinoma (TCC)...
  30. ncbi request reprint Flutamide administration at 500 mg daily has similar effects on serum testosterone to 750 mg daily
    Jeremiah C Murphy
    Section of Urology, Medical College of Georgia, Augusta, 30912, USA
    J Androl 25:630-4. 2004
    ..047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months...